+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
O

Actively Recruiting

Researchers are evaluating the effects of zigakibart on the progression of Immunoglobulin A Nephropathy IgAN, a kidney disease. This open-label, multicenter study involves adult participants with IgAN who are randomized into two groups differing only by the timing of an on-treatment kidney biopsy, either at the end of the first or second year of treatment. The study is sponsored by Novartis Pharmaceuticals and aims to assess kidney disease markers and dysfunction over time. Participants receive zigakibart as 600 mg subcutaneous injections every two weeks for up to two years 104 weeks. The total participation period may last up to 125 weeks, including an 8-week screening, the 104-week treatment period, and a 13-week safety follow-up. The study measures changes in kidney tissue IgA deposits, protein levels in urine, kidney function, and immune markers among others. Throughout the study, participants will undergo regular evaluations including kidney biopsies, blood and urine tests, and monitoring of side effects. Researchers will track changes in various disease and immune markers at multiple time points during and after treatment. Safety is closely monitored during the 13-week follow-up after treatment ends. The total commitment for participants can last nearly two and a half years.

Age: 18Years +All GendersPhase 2
30 locations
R

Actively Recruiting

Researchers are studying geographic atrophy GA secondary to age-related macular degeneration AMD to understand how different doses of the drug FWY003 affect the condition. This randomized, double-masked, multi-center study aims to characterize the dose-response relationship, as well as assess the efficacy and safety of FWY003 compared to a placebo in adults aged 50 and older with GA due to AMD. Participants are randomly assigned to receive one of three dose levels of FWY003 or a placebo. The study drug or placebo is administered as part of a controlled treatment plan over an 18-month period. The trial includes multiple study groups to compare effects across doses and between the active drug and placebo. During the study, participants will undergo regular assessments including measurements of GA lesion size, visual function tests such as best corrected visual acuity under regular and low luminance, contrast sensitivity, and plasma drug levels. Safety is monitored through adverse event tracking from the first dose through month 19. The main outcome is the change in GA lesion area from baseline to month 18, with treatment effects and safety followed over this period.

Age: 50Years +All GendersPhase 2
59 locations
E

Actively Recruiting

Researchers are evaluating the effects of therapeutic-dose heparin compared to usual care pharmacological thromboprophylaxis in patients hospitalized with community-acquired pneumonia CAP. The study focuses on the high incidence of hospitalizations due to CAP, which often leads to serious complications including thrombotic events that affect respiratory, cardiac, and other organs. This trial aims to explore whether therapeutic-dose heparin can improve outcomes by targeting inflammatory and thrombotic pathways, a strategy shown to help in COVID-19 but not yet studied in non-COVID-19 CAP. Participants are randomly assigned to one of two groups. One group receives therapeutic-dose low molecular-weight heparin LMWH or unfractionated heparin UFH daily for up to 14 days or until hospital discharge, whichever comes first. The other group receives the usual care thromboprophylaxis dose according to local practice, which is lower than the therapeutic dose. Treatments start as soon as possible after randomization. LMWH is preferred unless contraindicated, with dosing based on patient weight, while UFH may be used in cases of renal impairment. During the study, participants will be monitored for outcomes including survival at 30 days, bleeding events, thrombotic events, mechanical ventilation use, mortality at various timepoints, hospital-free days, and health-related quality of life. The study collects data up to 180 days after treatment. Safety monitoring includes tracking adverse events like bleeding and heparin-induced thrombocytopenia. Participation involves hospital stays expected to last at least 72 hours from randomization, with assessments throughout the treatment period and follow-up extending to 180 days.

Age: 18Years +All GendersPhase 3
68 locations